Health Trials

About this trial

Population:

Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).

Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.

These 5 cohorts will be subject to standardized clinical monitoring.

Eligibility criteria

Qualifiers

Diagnosis of juvenile idiopathic arthritis, rheumatoid arthritis and seronegative / psoriatic / undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis (ACR criteria).

Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.

Disqualifiers

Treated for > 3 months

> 50 years old

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,000 Participants
are grouped into 5 trial groups

Locations

1
UCLouvain1200, Brussels Belgium

Sponsors and collaborators

Université Catholique de Louvain

Lead sponsor

Source ClinicalTrials.gov